OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kelly on the Importance of Testing For Genetic Abnormalities in GIST

August 21st 2024

Ciara Kelly, MBBCh, BAO, discusses the importance of genetic abnormality testing for patients with gastrointestinal stromal tumors.

Dr McGregor on the Future Implications of Ongoing Research in RCC

August 21st 2024

Bradley McGregor, MD, discusses the future implications of evolutions in the renal cell carcinoma treatment paradigm.

Dr Semaan on Liquid Biopsy vs Tissue Biopsy for Detecting Sarcomatoid RCC

August 20th 2024

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

Dr Amanam on the Management of AEs Associated With JAK Inhibitors in Myelofibrosis

August 20th 2024

Idoroenyi Amanam, MD, discusses adverse effects associated with JAK inhibitors in myelofibrosis.

Dr Yee on Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in Early-Stage Breast Cancer

August 20th 2024

Douglas Yee, MD, discusses datopotamab deruxtecan and durvalumab in the neoadjuvant setting for early-stage breast cancer.

Dr Sonneveld on the FDA Approval of Subcutaneous Daratumumab Plus VRd in Myeloma

August 20th 2024

Pieter Sonneveld, MD, PhD, discusses the FDA approval of daratumumab plus VRd for select patients with newly diagnosed multiple myeloma.

Dr Tolaney on Frontline Treatment Approaches in HER2+ Breast Cancer

August 20th 2024

Sara M. Tolaney, MD, MPH, discusses standard frontline treatment approaches for patients with HER2-positive breast cancer.

Dr Subbiah on Outcomes With Larotrectinib in TRK Fusion–Positive Solid Tumors

August 20th 2024

Vivek Subbiah, MD, discusses data from the VICTORIA trial which evaluated treatment with larotrectinib in patients with TRK fusion–positive solid tumors.

Dr Shouse on AEs Associated With Targeted Therapies in FL

August 20th 2024

Geoffrey Shouse, DO, PhD, discusses adverse effects associated with targeted therapies used to treat patients with follicular lymphoma.

Dr McGregor on the Clinical Implications of the DAD-IO Trial in Urothelial Carcinoma

August 20th 2024

Bradley McGregor, MD, discusses the clinical implications of the DAD-IO trial in patients with metastatic urothelial carcinoma.

Dr Hernandez-Ilizaliturri on the Use of CAR T-Cell Therapy in R/R Multiple Myeloma

August 19th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Hood on the Association Between BRCA Mutations and Primary Tumor Location in PDAC

August 19th 2024

Ryan Hood, BA, discusses a study investigating the association between BRCA1/2 pathogenic variants and primary tumor location in pancreatic cancer.

Dr Tarhini on the Combination of High-Dose Bolus IL-2 and CTLA-4 Inhibition in Advanced Melanoma

August 19th 2024

Ahmad Tarhini, MD, PhD, discusses the hypothesis for investigating high-dose bolus IL-2 plus an anti–CTLA-4 agent in patients with advanced melanoma.

Dr Saliby on the Correlation Between Intermediate End Points and OS in RCC

August 19th 2024

Renee Saliby, MD, MSc, discusses the investigation of the correlation between intermediate end points and OS in metastatic renal cell carcinoma.

Dr Leidner on the DPV-001 Vaccine Plus PD-1 Inhibition in Metastatic HNSCC

August 19th 2024

Rom S. Leidner, MD, discusses the rationale for studying DPV-001 plus PD-1 inhibition in advanced or metastatic head and neck squamous cell carcinoma.

Dr Watts on the Final Results of the 2102-HEM-101 Trial in IDH1-Mutated AML

August 16th 2024

Justin M. Watts, MD, discusses the final 5-year results of the 2102-HEM-101 trial of olutasidenib in patients with IDH1-mutated acute myeloid leukemia.

Dr Tarhini on Hogh-Dose Bolus IL-2 With Ipilimumab Followed by Nivolumab in Melanoma

August 16th 2024

Ahmad Tarhini, MD, PhD, discusses the use of high-dose bolus IL-2 with ipilimumab followed by nivolumab in advanced melanoma following prior progression.

Dr Shah on Real-World Treatment and Outcomes in Metastatic RCC After IO/TKI Combos

August 16th 2024

Neil J. Shah, MBBS, discusses treatment patterns and clinical outcomes in metastatic renal cell carcinoma after an immuno-oncology/TKI combination.

Dr Piulats on Validating Predictive Biomarkers for Talazoparib Plus Enzalutamide in mCRPC

August 16th 2024

Josep Maria Piulats Rodriguez, MD, PhD, discusses next steps for validating predictive biomarkers of efficacy to treatment with talazoparib plus enzalutamide in mCRPC.

Dr Banerjee on Selecting Between Bispecific and CAR T-Cell Treatments in Myeloma

August 16th 2024

Rahul Banerjee, MD, FACP, discusses factors that may inform treatment selection when choosing between bispecific antibodies and CAR T-cell therapies in multiple myeloma